WALTHAM, Mass.--(BUSINESS WIRE)--Adnexus Therapeutics, Inc. today announced that the company will present data on CT-322, the company’s first Adnectin product candidate, at The Gordon Research Conference on Angiogenesis and Microcirculation held in Newport, Rhode Island, August 19-24. The poster to be presented this afternoon by Irvith Carvajal, Senior Scientist, Ph.D. is titled “CT-322: A novel specific VEGFR-2-blocking protein therapeutic agent that inhibits tumor growth in preclinical studies.”
